


What is claimed is:

1. A compound having Formula I:



or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^{1a} and R^{1b} are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, and C_{3-8} cycloalkyl;

R^{2a} and R^{2b} are independently selected from the group consisting of hydrogen, C_{1-6} alkyl, and C_{3-8} cycloalkyl;

R^3 is selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{4-8} heterocyclo,


R^4 is selected from the group consisting of C_{1-4} alkyl, and C_{3-6} cycloalkyl;

R^5 is halo;

R^6 is selected from the group consisting of C_{1-4} alkyl, and C_{3-6} cycloalkyl; and

R^7 is selected from the group consisting of hydrogen, C_{1-4} alkyl, and C_{3-6} cycloalkyl, with proviso that when R^{1a} , R^{1b} , R^{2a} , and R^{2b} are each hydrogen, then R^3 is selected from the group consisting of C_{3-6} cycloalkyl and C_{4-8} heterocyclo.

2. The compound of claim 1 having Formula II:



or a pharmaceutically acceptable salt or solvate thereof, wherein:

R^{1a} and R^{1b} are independently selected from the group consisting of hydrogen, C_{1-4} alkyl, and C_{3-6} cycloalkyl;


R^{2a} and R^{2b} are independently selected from the group consisting of hydrogen, C_{1-4} alkyl, and C_{3-6} cycloalkyl; and

R^3 is C_{3-6} heterocyclo containing one ring and one oxygen.

3. The compound of claims 1 or 2, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{1b} and R^{2b} are each hydrogen.

4. The compound of claim 3, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{1a} and R^{2a} are each hydrogen.

5. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, having Formula **III**:




wherein:

R^{1a} and R^{2a} are each independently C_{3-6} cycloalkyl;

R^3 is selected from the group consisting of hydrogen, C_{1-4} alkyl, C_{3-6} cycloalkyl, and C_{4-8} heterocyclo; and

the compound has an enantiomeric excess of 90% or more.

6. The compound of claim 3, or a pharmaceutically acceptable salt or solvate thereof, having Formula **IV**:



wherein:

R^{1a} and R^{2a} are each independently C_{3-6} cycloalkyl;

the compound has an enantiomeric excess of 90% or more.

V


the compound has an enantiomeric excess of 90% or more.

VI.

the compound has an enantiomeric excess of 90% or more.

9. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{1a} and R^{2a} are each cyclopropyl or cyclobutyl.

10. The compound of claim 2, or a pharmaceutically acceptable salt or solvate thereof, wherein R³ is selected from the group consisting of:



11. The compound of claim 1, or a pharmaceutically acceptable salt or hydrate thereof, selected from the group consisting of:

- 5-chloro-*N*²-(2-isopropoxy-5-methyl-4-(1,2,2,6,6-pentamethyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)-*N*⁴-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
- 5-chloro-*N*²-(2-isopropoxy-5-methyl-4-(2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)-*N*⁴-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
- 5-chloro-*N*²-(4-((cis)-2,6-diethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)-*N*⁴-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
- 5-chloro-*N*²-(4-((cis)-2,6-diethyl-1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)-*N*⁴-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
- 5-chloro-*N*²-(2-isopropoxy-5-methyl-4-(1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)-*N*⁴-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
- 5-chloro-*N*²-(2-isopropoxy-5-methyl-4-(1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)-*N*⁴-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
- 5-chloro-*N*²-(4-((cis)-2,6-dicyclobutyl-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)-*N*⁴-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
- 5-chloro-*N*²-(4-((cis)-2,6-dicyclobutyl-1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)-*N*⁴-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
- 5-chloro-*N*²-(4-((cis)-2,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)-*N*⁴-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
- 5-chloro-*N*²-(2-isopropoxy-5-methyl-4-((cis)-1,2,6-trimethyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)-*N*⁴-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
- 5-chloro-*N*²-(4-((trans)-2,6-diethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)-*N*⁴-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((cis)-2,6-dicyclopropyl-1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((trans)-2,6-dicyclobutyl-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((trans)-2,6-dicyclobutyl-1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((trans)-2,6-dicyclopropyl-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((trans)-2,6-dicyclopropyl-1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2S,6R)-2,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(2-isopropoxy-5-methyl-4-((2S,6R)-1,2,6-trimethyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2R,6R)-2,6-dicyclopropyl-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2R,6R)-2,6-dicyclopropyl-1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2R,6S)-2,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(2-isopropoxy-5-methyl-4-((2R,6S)-1,2,6-trimethyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2S,6S)-2,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(2-isopropoxy-5-methyl-4-((2S,6S)-1,2,6-trimethyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2R,6R)-2,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(2-isopropoxy-5-methyl-4-((2R,6R)-1,2,6-trimethyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2S,6S)-2,6-dicyclopropyl-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2S,6S)-2,6-dicyclopropyl-1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2R,6S)-2,6-dicyclopropyl-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2R,6S)-2,6-dicyclopropyl-1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2S,6R)-2,6-dicyclopropyl-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2S,6R)-2,6-dicyclopropyl-1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2R,6S)-2,6-dimethyl-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2R,6S)-2,6-dimethyl-1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2S,6S)-2,6-dimethyl-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2S,6S)-2,6-dimethyl-1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2R,6R)-2,6-dimethyl-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2R,6R)-2,6-dimethyl-1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2S,6S)-2,6-dicyclopropyl-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2S,6S)-2,6-dicyclopropyl-1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2R,6S)-2,6-dicyclopropyl-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro- N^2 -(4-((2R,6S)-2,6-dicyclopropyl-1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)- N^4 -(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;

5-chloro-*N*²-(4-((2*S*,6*R*)-2,6-dicyclopropyl-1-(tetrahydro-2*H*-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)-*N*⁴-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; and

5-chloro-*N*²-(4-((2*S*,6*R*)-2,6-dicyclopropyl-1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl)-2-isopropoxy-5-methylphenyl)-*N*⁴-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine.

12. The compound of claim 11, or a pharmaceutically acceptable salt or hydrate thereof, which is 5-chloro-*N*²-(2-isopropoxy-5-methyl-4-(1-(tetrahydro-2*H*-pyran-4-yl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)-*N*⁴-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine.

13. A pharmaceutical composition comprising the compound of any one of claims 1-12, or a pharmaceutically acceptable salt or hydrate thereof, and a pharmaceutically acceptable carrier.

14. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or the pharmaceutical composition of claim 13 for use in therapy.

15. Use of the compound of any one of claims 1-12, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or the pharmaceutical composition of claim 13, for the manufacture of a medicament for the treatment of cancer.

16. The use of claim 15, wherein the cancer is selected from the group consisting of anaplastic large-cell lymphoma, non-small cell lung cancer, diffuse large B-cell lymphoma, inflammatory myofibroblastic tumors, neuroblastoma, anaplastic thyroid cancer, rhabdomyosarcoma, breast cancer, colorectal cancer, esophageal squamous cell cancer, and renal cell carcinoma.